CN1193748C - Gardos通道拮抗剂 - Google Patents

Gardos通道拮抗剂 Download PDF

Info

Publication number
CN1193748C
CN1193748C CNB008054525A CN00805452A CN1193748C CN 1193748 C CN1193748 C CN 1193748C CN B008054525 A CNB008054525 A CN B008054525A CN 00805452 A CN00805452 A CN 00805452A CN 1193748 C CN1193748 C CN 1193748C
Authority
CN
China
Prior art keywords
substituent
compound
ring
compounds
acetamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008054525A
Other languages
English (en)
Chinese (zh)
Other versions
CN1344158A (zh
Inventor
G·A·麦克诺顿－史密斯
G·C·里格登
J·W·施特克尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icagen Inc
Original Assignee
Icagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icagen Inc filed Critical Icagen Inc
Publication of CN1344158A publication Critical patent/CN1344158A/zh
Application granted granted Critical
Publication of CN1193748C publication Critical patent/CN1193748C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNB008054525A 1999-02-23 2000-02-10 Gardos通道拮抗剂 Expired - Fee Related CN1193748C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13551199P 1999-02-23 1999-02-23
US09/386,601 1999-08-31
US60/135,511 1999-08-31
US09/386,601 US6288122B1 (en) 1999-02-23 1999-08-31 Gardos channel antagonists

Publications (2)

Publication Number Publication Date
CN1344158A CN1344158A (zh) 2002-04-10
CN1193748C true CN1193748C (zh) 2005-03-23

Family

ID=26833406

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008054525A Expired - Fee Related CN1193748C (zh) 1999-02-23 2000-02-10 Gardos通道拮抗剂

Country Status (16)

Country Link
US (1) US6288122B1 (2)
EP (1) EP1158971B1 (2)
JP (2) JP4038337B2 (2)
KR (1) KR100705726B1 (2)
CN (1) CN1193748C (2)
AP (1) AP1465A (2)
AT (1) ATE370728T1 (2)
AU (1) AU762039B2 (2)
BR (1) BR0008416A (2)
CA (1) CA2371857C (2)
DE (1) DE60036093T2 (2)
ES (1) ES2291191T3 (2)
HK (1) HK1045262B (2)
IL (2) IL145012A0 (2)
OA (1) OA11838A (2)
WO (1) WO2000050026A1 (2)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004010A1 (en) * 2001-07-06 2003-01-16 Poseidon Pharmaceuticals A/S Carbonylamino derivatives useful for obtaining immune regulation
EP1465863B1 (en) 2002-01-04 2008-07-09 NeuroSearch A/S Potassium channel modulators
AU2003217810C9 (en) * 2002-02-28 2008-06-12 Icagen, Inc. Methods for treating diseases related to intraocular pressure
WO2005003143A1 (en) * 2003-07-03 2005-01-13 Poseidon Pharmaceuticals A/S Novel potassium channel modulators
WO2005003094A1 (en) * 2003-07-03 2005-01-13 Poseidon Pharmaceuticals A/S Diarylmethyl derivatives as potassium channel modulators
WO2006084031A1 (en) * 2005-02-01 2006-08-10 Icagen, Inc. Imines as ion channel modulators
US20100056637A1 (en) * 2005-12-20 2010-03-04 Icagen, Inc. Treatment methods using triaryl methane compounds
EP1968563A4 (en) * 2005-12-20 2010-05-19 Icagen Inc TREATMENT METHODS USING TRIARYLMETHANE COMPOUNDS
PT2192896E (pt) 2007-08-24 2011-04-04 Neurosearch As Derivados de carbonilamino úteis para o tratamento de doença inflamatória intestinal
US20090076157A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched senicapoc
EA023596B1 (ru) 2008-04-09 2016-06-30 Сирус Корпорейшн Способы обработки композиции эритроцитов для инактивации патогена
EP2358750B1 (en) 2008-11-10 2017-01-11 Boehringer Ingelheim International GmbH Compositions and methods for modulating cell-cell fusion via intermediate-conductance calcium-activated potassium channels
WO2016134353A1 (en) * 2015-02-20 2016-08-25 Children's Medical Center Corporation Methods for treating malaria using potassium channel inhibitors
EP3106155A1 (en) 2015-06-15 2016-12-21 Universite d'Aix Marseille Treatment and diagnosis of hereditary xerocytosis
AU2017350760B2 (en) * 2016-10-25 2022-03-31 Paracelsus Neuroscience I, LIc Use of senicapoc for treatment of neuropathic pain
WO2018162426A1 (en) 2017-03-06 2018-09-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment and diagnosis of hereditary xerocytosis
WO2020198939A1 (zh) * 2019-03-29 2020-10-08 深圳仁泰医药科技有限公司 2,2-双(4-氟苯基)-2-苯乙酰胺的晶型a及其制备方法和应用
US12186286B2 (en) * 2019-07-29 2025-01-07 Paracelsus Neuroscience Llc Use of senicapoc for treatment of stroke
CN115943138A (zh) * 2020-07-14 2023-04-07 阿迪玛生物有限责任公司 包含gardos通道拮抗剂的组合物及其用途
CA3201648A1 (en) * 2020-12-11 2022-06-16 Robin VAN BRUGGEN Treatment and prevention of anaemia of inflammation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273992A (en) 1992-11-02 1993-12-28 Beth Israel Hospital Assoc. Inc. Method for reducing sickle erythrocyte dehydration and delaying the occurrence of erythrocyte sickling in-situ
WO1997034589A1 (en) 1996-03-20 1997-09-25 President And Fellows Of Harvard College Triaryl methane compounds for sickle cell disease

Also Published As

Publication number Publication date
JP4038337B2 (ja) 2008-01-23
DE60036093T2 (de) 2008-05-15
IL145012A0 (en) 2002-06-30
KR100705726B1 (ko) 2007-04-11
AP1465A (en) 2005-09-22
AU2880700A (en) 2000-09-14
JP2007262075A (ja) 2007-10-11
AU762039B2 (en) 2003-06-19
EP1158971A4 (en) 2003-04-16
IL145012A (en) 2006-12-10
AP2001002268A0 (en) 2001-09-30
US6288122B1 (en) 2001-09-11
BR0008416A (pt) 2002-01-29
CA2371857A1 (en) 2000-08-31
OA11838A (en) 2005-08-22
WO2000050026A1 (en) 2000-08-31
EP1158971A1 (en) 2001-12-05
CN1344158A (zh) 2002-04-10
ATE370728T1 (de) 2007-09-15
HK1045262A1 (en) 2002-11-22
DE60036093D1 (de) 2007-10-04
ES2291191T3 (es) 2008-03-01
HK1045262B (zh) 2005-07-29
EP1158971B1 (en) 2007-08-22
KR20020002393A (ko) 2002-01-09
CA2371857C (en) 2008-07-29
JP2002537331A (ja) 2002-11-05

Similar Documents

Publication Publication Date Title
CN1193748C (zh) Gardos通道拮抗剂
CN1012433B (zh) 白三烯拮抗剂的制备方法
CN85107020A (zh) 烷基亚磺酰胺基苯基烷基胺的制备方法
CN1255136A (zh) 取代的4－芳基亚甲基－2－亚氨基－2,3－二氢噻唑和衍生物及其药学应用
CN1033043A (zh) 新的抗抑郁剂的制法
CN1261877A (zh) 4－溴或4－碘苯基氨基苯氧肟酸衍生物及其作为mek抑制剂的用途
CN1589264A (zh) 用于治疗恶性肿瘤的方法
CN1051551C (zh) 新型吡咯并咔唑衍生物
CN1791576A (zh) 代谢型谷氨酸受体的苯甲酰胺调节剂
CN1072927A (zh) 新的n-羟烷基取代的1，2，3，6-四氢吡啶和哌啶衍生物
CN1109870A (zh) N-(3-氨基丙基)-n-苯基-5，6，7，8-四氢化萘-2-羧酰胺衍生物衍生物、制法及应用
CN87100686A (zh) 用作心血管剂的3-烷氧基-2-氨基丙胺类化合物
CN86103227A (zh) 制备2-吡咯烷酮衍生物的方法
CN1126990A (zh) 新的(1-苯基-1-杂环基)烷烃衍生物和作为神经保护剂的应用
CN88101782A (zh) 抗心律不齐药
CN1092074A (zh) 二氮杂䓬衍生物
CN1014515B (zh) 制备mao抑制剂—非芳香族氟烯丙胺的方法
CN1960974A (zh) 烷基取代的哌啶衍生物及其作为单胺神经递质再摄取抑制剂的用途
CN1228338C (zh) 咪唑衍生物或其盐以及含有该衍生物或其盐的药物
CN1091632A (zh) 药剂
CN1182416A (zh) 用于神经变性疾病治疗的苯甲酰胺类化合物
CN1112113A (zh) 新的三唑化合物及其制备方法和用途
CN1177852C (zh) 膦酸二酯衍生物
CN1914169A (zh) 作为环氧合酶－2抑制剂的二芳基－2－(5h)－呋喃酮的氧化氮释放前药
CN1870993A (zh) 基于咪唑克生盐或其一种多晶型物的药物组合物

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050323

Termination date: 20140210